Shilpa Medicare Investor Presentation for Quarter Ended 30 September 2025
Shilpa Medicare releases investor presentation for quarter ended September 30, 2025, reporting revenue growth of 8% YoY for H1 FY26 and EBITDA growth of 20% YoY. Concall on November 17, 2025.
The financial results indicate a positive trend for the company. New product launches and strategic partnerships could drive future growth.
The announcement highlights strong financial performance, including revenue and EBITDA growth, along with strategic initiatives like new product launches and partnerships.
* Shilpa Medicare Limited has released its Investor Presentation for the quarter ended 30 September 2025. * The company reported revenue of ₹700 crore for 1H FY26, a growth of 8% YoY, and an EBITDA of ₹208 crore, up 20% YoY. * Highest quarterly revenue at ₹372 crore, grew by 7% on YoY basis; driven by growth in API and FDF verticals * Highest quarterly EBITDA at ₹110 crore growing 21% YoY with EBITDA Margins expanding to 30%. * PAT of ₹91 crore in 1HFY26 surpasses full year FY25 PAT of ₹78 crore. * The API segment experienced growth, driven by both Onco and Non-Onco portfolios. * The Formulations business saw healthy growth of approximately 16% YoY. * Shilpa is gearing up to launch NorUDCA in 3QFY26, a novel first-in-class therapy for NAFLD in India, partnering with three leading Indian companies for marketing. * Positive Phase 3 results for Ondansetron Extended-Release Injection, with launch planned in early 2026. * Biologics division is accelerating innovation, with key NBEs advancing towards Phase 1 trials in FY27 and major biosimilars progressing in clinical development. * Earnings conference call will be held on 17 November 2025 at 11:00 IST. * Management Commentary: I am pleased to report another quarter of strong performance, building on the positive momentum from 1QFY26. The quarter saw revenue growth of 7%, with highest quarterly revenue and EBITDA, having robust EBITDA margins of ~30%.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.